Table 4 TEAEs occurring in ≥2% of patients in any treatment group: safety population
Number (%) of patients reporting TEAEs | |||||||
|---|---|---|---|---|---|---|---|
Placebo N = 59 | Salbutamol 400 μg N = 58 | Abediterol 0.313 μg N = 60 | Abediterol 0.625 μg N = 60 | Abediterol 1.25 μg N = 60 | Abediterol 2.5 μg N = 61 | Total N = 62 | |
Any TEAE | 16 (27.1) | 12 (20.7) | 18 (30.0) | 16 (26.7) | 18 (30.0) | 23 (37.7) | 51 (82.3) |
Headache | 7 (11.9) | 6 (10.3) | 4 (6.7) | 7 (11.7) | 8 (13.3) | 7 (11.5) | 26 (41.9) |
Nasopharyngitis | 1 (1.7) | 0 | 8 (13.3) | 3 (5.0) | 4 (6.7) | 2 (3.3) | 17 (27.4) |
Chest discomfort | 2 (3.4) | 0 | 1 (1.7) | 0 | 0 | 2 (3.3) | 5 (8.1) |
Wheezing | 1 (1.7) | 2 (3.4) | 1 (1.7) | 0 | 1 (1.7) | 0 | 4 (6.5) |
Oropharyngeal pain | 0 | 1 (1.7) | 0 | 1 (1.7) | 0 | 3 (4.9) | 4 (6.5) |
Cough | 2 (3.4) | 0 | 0 | 1 (1.7) | 0 | 0 | 3 (4.8) |